# A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status

> **NCT05669092** · PHASE3 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 174 (estimated)

## Conditions studied

- Toripalimab
- Radiation

## Interventions

- **DRUG:** Toripalimab
- **RADIATION:** CRT
- **RADIATION:** SCRT
- **DRUG:** XELIRI
- **DRUG:** FOLFRINOX

## Key facts

- **NCT ID:** NCT05669092
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 174 (ESTIMATED)
- **Last updated:** 2022-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05669092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05669092, "A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05669092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*